NovelStem International Corp. (NSTM) stock
Close on Oct 19, 2026Market cap $493.32KP/E –Yield –
Key statistics
Valuation at the latest close; fundamentals over fiscal , balances at Jun 30, 2026
Valuation
- Market cap
- $493.32K
- P/E ratio
- –
- Price to sales
- –
- Price to book
- –
- Dividend yield
- –
- Free cash flow yield
- –
Fundamentals
- Net income
- -$307.56K
- EPS, diluted
- $0.00
- Book value per share
- -$0.04
- Diluted shares
- 49M
Trading
- Previous close
- $0.01
- Open
- $0.01
- Day's range
- $0.01 – $0.01
- Volume
- 0
Market cap history
Month-end market cap since 2011, using shares outstanding reported at the time
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Oct 19, 2026. The S&P 500 is measured by the SPY fund.
| Period | NSTM | S&P 500 | Difference | NSTM per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | 0.0% | +0.6% | −0.6 pts | ||
| 3 months | 0.0% | +3.4% | −3.4 pts | ||
| Year to date | 0.0% | +13.3% | −13.3 pts | ||
| 1 year | -50.0% | +16.6% | −66.6 pts | ||
| 3 years | -92.3% | +86.4% | −178.7 pts | -57.5% | +23.1% |
| 5 years | -96.7% | +81.9% | −178.5 pts | -49.4% | +12.7% |
| 10 years | -98.7% | +318.9% | −417.5 pts | -35.1% | +15.4% |
Eleven years at a glance
Fiscal years 2008 to 2025 and trailing twelve months, USD
Revenue
Operating income
Net income
EPS, diluted
Free cash flow
Press releases
Releases NovelStem International filed with the SEC as exhibits to Form 8-K or 6-K
About NovelStem International
Retail-Retail Stores, NEC
NovelStem International Corp. operates as a holding company focused on biotechnology assets. The company previously held an equity stake in NewStem Ltd, a development-stage Israeli biotech company specializing in human pluripotent stem cells for oncology drug discovery and cancer diagnostics. Following NewStem’s liquidation and the sale of its interest in the NetCo joint venture, NovelStem’s primary asset consists of rights to future licensing proceeds and profits from proprietary stem cell technology relicensed by Yissum Research Development Company. Potential customers for this technology comprise healthcare institutions, oncologists, and pharmaceutical licensees.
Company profile, executives and historyNovelStem International stock: common questions
What is NovelStem International's stock price?
NSTM closed at $0.01 on Oct 19, 2026, up 0.00% on the day.
What is NovelStem International's market cap?
NovelStem International was worth $493.32K at the close on Oct 19, 2026: the share price times the diluted shares outstanding.
What is NSTM's P/E ratio?
NovelStem International lost money over the twelve months to Jun 30, 2026 (diluted EPS $0.00), so it has no meaningful P/E ratio.
Does NovelStem International pay a dividend?
No. NovelStem International has not paid a cash dividend over the last twelve months.
How has NSTM stock performed over the past year?
Including dividends, NSTM returned -50.0% over the past year, against +16.6% for the S&P 500.
Who are NovelStem International's competitors?
Companies most similar to NovelStem International by business, industry and size include RMTG, RCT, NEGG, RERE, BQ.
See a number that looks wrong?